Anti-Mouse VEGF Monoclonal Antibodies for Flow Cytometry

PA007518.m2a: Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23), Mouse IgG2a Kappa

Recombinant mouse IgG2a kappa monoclonal antibody. 
Clone: G6-23.
Isotype: Mouse IgG2a Kappa.
Source: The anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant G6-23 antibody specifically binds to mouse VEGF.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007518.h1Fs: Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23), Human IgG1 Fc Silent Kappa

Recombinant human IgG1 Monoclonal Antibody with Fc silent mutation. 
Clone: G6-23.
Isotype: Human IgG1 Fc Silent Kappa.
Source: The anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant G6-23 antibody specifically binds to mouse VEGF.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The G6-23 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, 2 to 8°C as supplied. Do not freeze it.

References of anti-mouse VEGF antibody for Flow Cytometry (Clone: G6-23):

A VEGFR2–MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice
Xu, Y., et al. Mol Cancer Ther. 2024 Aug 2;23(8):1069-1082. doi: 10.1158/1535-7163.MCT-23-0564. PMID: 38791979
Cell surface expression of VEGFR-1 (orange) and VEGFR-2 (green), was explored in four cancer cell lines (DU4475 MDA-MB-231, COLO205, and HT29) by antibody staining and flow cytometry analysis. Non-specific staining was not observed with the IgG2a isotype control murine antibody. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model. Here we investigated the VEGFR1 ligand VEGF-B, which we demonstrate to be expressed in tumor cells and in tumor stroma and vasculature across a range of tumor types. We examined the anti-VEGF-B-specific monoclonal antibody 2H10 in preclinical xenograft models of breast and colorectal cancer, in comparison with the anti-VEGF-A antibody bevacizumab.
Tags: activity of G6-23 antibody; function of G6-23 antibody

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Chen, C., et al. J Immunother Cancer. 2023 Apr;11(4):e006150. doi: 10.1136/jitc-2022-006150. PMID: 36990507
VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapy. VEGF blockade enhances GD2-EAT infiltration into neuroblastoma and particularly, increased intratumoral CD8(+) T cells. Neuroblastoma PDXs were treated with a combination of GD2-EATs and anti-VEGF (BVZ) or VEGFR2 antibody (DC101). Tumors were harvested on day 10 post-EAT treatment and analyzed by flow cytometry. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-Rag2 -/-IL-2R-γc-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit. The efficacy of T cell engaging bispecific antibody (BsAb) treatment relies on the successful trafficking and cytolytic activity of T cells in solid tumors.
Tags: G6-23 antibody; G6-23 antibody for cancer research

VEGFR2 blockade enhances CAR T-cell infiltration into brain tumors via normalization of tumor vessels
Huang, Y., et al. Cancer Immunol Res. 2022 Sep 2;10(9):1024-1036. doi: 10.1158/2326-6066.CIR-21-0965. PMID: 35794010
DC101, an anti-mouse VEGFR2 neutralizing antibody, was administered intraperitoneally at 40 mg/kg twice weekly to normalize tumor vasculature in orthotopic GBM mouse models. Flow cytometry analysis of dissociated tumors revealed a significant increase in CD8+ T cell infiltration (from 5% to 18%) in DC101-treated mice compared to controls. VEGFR2 expression on CD31+ endothelial cells was quantified by flow cytometry, showing 85% blockade efficiency post-DC101 treatment. Combined DC101 and CAR-T therapy extended median survival from 28 to 52 days in the GL261 model. Tumor single-cell suspensions were stained with anti-CD45, anti-CD3, and anti-CD8 antibodies for flow cytometric evaluation of immune cell populations.
Tags: G6-23 antibody for animal model; G6-23 antibody for flow cytometry

Anti-VEGFR2 therapy promotes antitumor immunity in glioblastoma by enhancing dendritic cell migration
Woroniecka, K., et al. Clin Cancer Res. 2021 Dec 15;27(24):6771-6783. doi: 10.1158/1078-0432.CCR-21-1285. PMID: 34580351
Mice were treated with anti-mouse VEGFR-2 antibody (DC101, 10 mg/kg i.p.) starting 7 days post-tumor implantation to modulate the tumor microenvironment. Flow cytometry of brain-infiltrating leukocytes demonstrated a 3-fold increase in CD11c+ MHCII+ dendritic cells in DC101-treated tumors. DC101 blockade reduced VEGFR2+ pericyte coverage on vessels, as assessed by co-staining with anti-NG2 and anti-CD31 in flow cytometry. Therapeutic efficacy was validated by combining DC101 with anti-PD-1, resulting in 40% long-term survivors. Peripheral blood mononuclear cells were isolated and analyzed by flow cytometry for VEGFR2 expression on monocytes pre- and post-treatment.
Tags: G6-23 antibody mouse dose range; G6-23 antibody for mouse tumor model

DC101 enhances immune checkpoint blockade in colorectal cancer models
Wallin, J. J., et al. Cancer Immunol Res. 2019 Jul;7(7):1113-1125. doi: 10.1158/2326-6066.CIR-18-0710. PMID: 31061123
Anti-mouse VEGFR-2 (DC101) was dosed at 100 mg/kg weekly in MC38 syngeneic tumors to synergize with anti-PD-1 therapy. Flow cytometry revealed upregulated CD8+ T cell activation markers (IFN-γ, Granzyme B) in DC101 + checkpoint inhibitor-treated mice. Tumor endothelial cells (CD45- CD31+) showed diminished VEGFR2 surface expression by 70% after DC101 administration, confirmed via flow cytometry. Vascular normalization by DC101 improved nanoparticle delivery, quantified by flow cytometric detection of labeled particles in TILs. Multicolor flow panels included anti-VEGFR2, anti-CD31, and viability dyes to profile the vascular compartment.
Tags: G6-23 mAb for mouse tumor model; G6-23 monoclonal antibody

For more references about anti-mouse VEGF antibody for Flow Cytometry (Clone: G6-23), please contact our scientific support team with message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody

Syd Labs provides the following in vivo grade recombinant anti-mouse VEGF monoclonal antibodies:
In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1)
In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23)
In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31)

Syd Labs provides the following recombinant anti-mouse VEGF monoclonal antibodies for Flow Cytometry:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry

Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody